Background
Apolipoprotein B mRNA-editing catalytic polypeptide like-3G (APOBEC3G) deaminates cytidine (C) to uracil (U) in the negative strand of HIV genome and subsequently guanine (G) to adenine (A) on the positive strand leading to G to A hypermutation. [1] Hypermutated HIV genome is prone to degradation. Hypermutation also introduces multiple stop codons in the HIV reading frame, reducing viral fitness. [2] A hypermutated HIV-1 variant has reduced transmission fitness. HIV counteracts antiviral activity of APOBEC3G through the viral infectivity factor (Vif) targeting APOBEC3G for degradation. [3] APOBEC3G antiviral activity presents a potential therapeutic target against HIV. However, the role of polymorphisms in APOBEC3G on the risk of HIV infection and disease progression remains contested. A study by An et al. [4] reported seven single nucleotide polymorphisms (SNPs) in APOBEC3G, three in the promoter, and two each in exons and introns. [4] APOBEC3G c.557A>G (p.H186R) in exon 4 is the most studied SNP and APOBEC3G c.557G/G genotype and c.557G allele have been linked to accelerated HIV disease progression compared with other c.557A carrying genotypes and the c.557A allele in adults. [4, 5] In paediatric populations, the c.557G/G genotype has been linked to faster decline in CD4 T-cell count [6] and greater tendency to central nervous system impairment when compared with the c.557A/A and c.557 A/G genotypes. [7] However, the influence of APOBEC3G genetic polymorphisms in vertical transmission of HIV remains unknown.
A study measuring APOBEC3G mRNA levels in human cells from different groups of HIV-positive people reported that mRNA abundance followed the order: long-term non-progressors>HIV uninfected>progressors, with the mRNA levels correlating positively with CD4 T-cell counts and inversely with viral loads. [8] Kikuchi and colleagues [9] reaffirmed the importance of APOBEC3G activity in HIV with a demonstration of attenuation of anti-APOBEC3G activity of HIV-1 Vif protein in elite HIV controllers. These observations suggest that increased APOBEC3G expression may slow progression of disease in HIV infected individuals. Literature on APOBEC3G genetic polymorphisms is available for most world populations, but with very little coverage of African populations; yet, these African populations possess the most genetic diversity; thus findings from other populations may not always explain what is found in Africans. This study, therefore, describes THE NEW MILLENNIUM polymorphisms in APOBEC3G and their role in predicting risk of HIV infection in children by evaluating distribution of APOBEC3G variants in three groups of children:
• Children born to HIV-infected mother and born infected (exposed and infected, EI); • Children born to HIV-infected mothers and born uninfected (exposed but uninfected, EUI); and • Children born to uninfected mothers (unexposed, uninfected, UEUI). Frequencies of APOBEC3G variants were also compared with other African and world populations.
Methods

Study participants
A cross-sectional study of APOBEC3G gene polymorphisms and their possible association with HIV infection in HIV-exposed children was conducted. Participants were recruited from the Better Health for the African Mother and Child (BHAMC) cohort, a longitudinal study of mother-child pairs followed up between 2002 and 2012, as described elsewhere. [10] In summary, the participants were 104 unrelated children aged 7 to 9 years, of bantu African origin. These included 32 children perinatally infected with HIV (EI) who were available in the cohort at the time of collection, and 72 healthy HIV-uninfected children comprising 36 exposed to HIV in utero but not infected (EU) and 36 unexposed and uninfected (UEUI). The EU and UEUI groups were combined to form the controls. Written informed consent was obtained from each child's parent or legal guardian before the samples were collected. The study received ethics approval from the Medical Research Council of Zimbabwe and the University of Cape Town Faculty of Health Sciences Research Ethics Committee.
Genotyping of APOBEC3G gene variants
Genomic DNA was extracted from blood samples using the Nucleospin Blood L kit (Macherey-Nagel, Germany) according to the manufacturer's instructions. Five SNPs were investigated in the APOBEC3G gene; two in the promoter region (g.-571G>C, rs5757463 and g.-90C>G, rs5750743), one in exon 4 (c.557A>G, rs8177832) and two in introns (c.467-85T>C, rs3736685 and c.582-162C>G, rs2294367).
Variation at c.557A>G and g.-90C>G were genotyped using polymerase chain reaction-restriction fragment polymorphism (PCR-RFLP) whilst SNaPshot was used to genotype the remaining three. The APOBEC3G c.557A>G polymorphism was determined using a method previously described elsewhere but with minor modifications. [4] A 409bp DNA fragment flanking the c.557A>G site was generated from a PCR reaction. The PCR product was subsequently digested using 2 U of HhaI (Fermentas, Canada) restriction enzyme. The G allele resulted in the generation of three fragments: 194bp, 145bp and 70bp, while the A allele resulted in only two bands: 339bp and 70bp. Genotyping for APOBEC3G g.-90C>G involved amplification of a 355bp fragment flanking the SNP in a PCR reaction and digestion of the PCR products with 5 U of AvaI (Fermentas, Canada) to determine the allelic variants. The C variant resulted in two fragments, 259bp and 96bp whilst the G variant was undigested, presenting as a 355bp fragment.
The PCR based primer extension (SNaPshot) method was used to genotype three SNPs in the APOBEC3G gene; g.-571G>C, c.467-85T>C and c.582-162C>G. Three sets of sense and antisense primer pairs were designed to amplify three DNA fragments flanking SNPs: rs5757463G>C (Forward-GCAAATGCATCCCT TGT-GTA, Reverse-CCTCCTCTCCACCATCAAGA), rs3736685T>C (Forward-TAC CCTGACCATCTTTGTTGC, Reverse-ACA-CGAACTTGCTCCAACAGT) and rs2294367C>G (Forward-GTG-AGGCCAGGGAAGAAGA, Reverse-TGA AAG TGA ATG TGG-GTG GA), respectively. Genotyping of APOBEC3G g.-571G>C and c.582-162C>G variants was done simultaneously in a multiplex SNaPshot reaction. The reaction contained g.-571G>C primer (AATTTGTAGGTCACCACGCCATAGGAACACACTACCA) and c.582-162C>G primer (TGGCACTGACTGTAACTAGTATC). To determine the g.-571G>C and c.582-162 alleles, the SNaPshot products were analysed through capillary electrophoresis. Unlike g.-571G>C and c.582-162C>G SNPs that were genotyped in a multiplex SNaPshot, c.467-85T>C variants were determined in a singleplex SNaPshot, using 20 pmol of the primer (ACATCCCTTAG AATCTTGTCAGAAGAGGTTCCCACT TAC TTG CTA).
Statistical analysis
Genotype and allele frequencies were calculated using Stata version 11.2 (StataCorp LP, USA) and/or SHEsisPlus online version. [11] Hardy Weinberg Equilibrium (HWE) was tested using χ 2 or Fisher's exact test with one degree of freedom. Chi-squared and Fisher's exact tests were used, where appropriate, to test homogeneity in alleles and genotypes among the participant groups. p<0.05 was considered statistically significant for all comparisons. Pairwise linkage disequilibrium (LD) analyses between APOBEC3G SNPs were carried out using SHEsisPlus and haplotypes were inferred using the expected maximisation algorithm. During inference of haplotypes, each chromosome of a homologous pair was considered individually, giving a total of two times the number (2n) of individuals included in the analysis. 
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Results
Demographic characteristics and association of APOBEC3G polymorphisms with HIV infection
Demographic characteristics of participants are described elsewhere [10] and are summarised in Table 1 . Haplotype frequencies were compared between the HIV-infected children and HIV-uninfected. Haplotypes with frequencies less than 0.03 were excluded from analysis. Table 3 
Baseline allele frequencies and their comparison with other populations
We report frequencies for minor alleles in the HIV-uninfected (EU+UEUI) Zimbabwean population: APOBEC3G c.557G (40%), 
Discussion
This study describes genetic variation at five APOBEC3G loci and its association with HIV infection in Zimbabwean children born to HIVinfected mothers. The frequency of 40% for the c.557G allele in the Zimbabwean population is slightly higher than that observed among black South Africans (30%) [4] and African Americans (37%) [5] but much higher than observed in Caucasians (<5%) [4] and Asians (0%). The APOBEC3G c.557A>G polymorphism results in a significant functional effect due to the histidine to arginine (p.H186R) that alters APOBEC3G [12] In addition to the possible effects of p.H186R amino acid alteration, APOBEC3G activity is determined by amount of enzyme available in circulation. [8] Inter-individual variation in circulating APOBEC3G may be a result of polymorphism in the gene's promoter and other regulatory sequences including those at exon-intron junctions or used by spliceosomes.
There is limited information on the frequency and distribution of APOBEC3G alleles in different populations. The frequency of the g.-90C allele in our study is lower than among the YRI (32% v. 44%) but higher than among Caucasians (4%). The distribution of APOBEC3G c.467-85C allele frequency was also comparable between Zimbabweans (42%) and YRI (48%) but higher than that observed among Caucasians (4%) and Asians (5%). Frequencies of g.-571C and c.467-85C alleles were generally higher among Africans compared with Caucasians. Variant c.582-162G allele was more frequent among Caucasians (58%) and Asians (66%) compared with Zimbabweans (6%) and YRI (4%). The distribution of APOBEC3G alleles c.557G, g.-90C, c.467-85C and c.582-162G in the world mirrors distribution of HIV cases, where the highest prevalence is in sub-Saharan Africa where the highest number of HIV-infected people are found, compared with Europe and Asia. This suggests that APOBEC3G genetic variation may be contributing to the differences in susceptibility to HIV infection observed in different world populations. This supports findings by Skelton et al. [13] reporting on differential distribution of BST-2 variants, which also mirrors HIV infection prevalence in Africa. [13] Despite the relationship between APOBEC3G variants and HIV prevalence in different populations, analysis of individual APOBEC3G SNPs may not be a good predictor of risk of HIV infection. Our findings support observations by An et al. [4] who, in a multicentre study involving highly exposed seronegative and HIV-seropositive individuals, did not observe any association between APOBEC3G variants and HIV status. However, the c.581+68T allele of a c.581+68C>T SNP (rs17496018) in exon 4 of the APOBEC3G gene, which did not form part of this study, was associated with increased risk of HIV transmission. [6] These observations on APOBEC3G gene variation suggest that individual allelic variants may fail to show any effect on their own. However, their collective contribution to gene expression or overall protein structure may be important, as we have shown with other genes. [10, [13] [14] [15] In an effort to understand the combinational effect of APOBEC3G polymorphism on HIV transmission haplotype, frequencies were compared between HIV-infected and uninfected groups of children. LD was generally strong between pairs of the APOBEC3G SNPs studied in the population. This conforms to studies in Argentinians, Caucasians and African Americans, where all five SNPs investigated as part of this study have been reported to be in strong LD. [4] This implies a higher likelihood of co-inheritance of these APOBEC3G SNPs; thus, they may collectively influence risk of HIV infection and disease progression. Nonetheless, haplotype analysis of the SNPs failed to show association with risk of HIV infection further; hence, the collective role of APOBEC3G polymorphisms in HIV may be negligible.
The interpretation of the effect of APOBEC3G genetic variation in HIV infection and disease progression is difficult due to underlying genetic factors. Polymorphisms in other APOBEC genes such as APOBEC3F have also been linked with differential antiretroviral activity of their protein products. Given the complex network of interaction of proteins in the cytidine deamination antiviral pathway, determination of association between APOBEC3G genetic variants and HIV infection or disease progression would require large sample sizes and adjusting for other proteins involved, a motivation for genomewide association studies. Findings of this study may have been limited by the sample size, and unavailability of maternal virological and immunological information that may have influenced vertical transmission of HIV. Furthermore, the cross-sectional nature of the study makes it difficult to establish the causal relationship between APOBEC3G genotypes and HIV transmission. A longitudinal study using a bigger sample size and taking a pathway approach could be ideal. 
